Typical Nasal Cannula offer pure source oxygen at flow rates of 1 to 6 L/min using straightforward nose prongs. At flow rates more than 6 L/min, oxygen supply only slightly improves due to the resistance of the tubing and the air flow becoming more turbulent. Moreover, individuals may find it challenging to endure the gas velocity experienced by small-bore Nasal Cannula at high flow rates. In general, the nasal cannula is well tolerated at suitable flow rates between 1 and 6 L/min. Thus, 6 L/min equates to a fractional concentration of oxygen in inspired gas of around 40–45%. The fractional concentration of oxygen in inspired gas provided rises relative to flow rate at a rate of about 3-4% per L/min.
The fractional concentration of oxygen in inspired gas varies with the patient's respiratory effort, which is a drawback of this fixed low-flow delivery technique.To prevent drying out of the nasal mucosa, the system must be utilised at flow rates of no more than 4 L/min. The patient's inspiratory flow rate determines the inspired oxygen concentration, which typically ranges from 22% to 28%. The nasopharynx functions as a small reservoir at flow rates of 2 to 4 L/min, increasing FIO2 during the expiratory pause.
The manner of breathing (mouth or nose) and the placement of the Nasal Cannula then have an impact on the amount of FIO2 that is given. In respiratory distress, when respiratory rate and tidal volumes rise, higher portions of ambient air are inspired, resulting in decreasing fractional oxygen concentrations in inspired gas supplied. The technology also has disadvantages related to the need for nasal patency and the inconsistent fractional oxygen content in inspired gas while breathing through the mouth as opposed to the nose, according to research. The nasopharyngeal mucosa can become dry from prolonged use of nasal Cannula at high flow rates, so source oxygen should be humidified.
Moreover, this market report also covers regional and country markets in detail.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the High Flow Nasal Cannula market include Great Group Medical Co., Ltd., Salter Labs, TNI Medical Ag, Mek-Ics Co., Ltd., Flexicare Medical Limited.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global High Flow Nasal Cannula Market Research Report" by requesting FREE Sample Copy at https://www.valuemarketresearch.com/contact/high-flow-nasal-cannula-market/download-sampleMarket DynamicsRespiratory distress is one of the most common causes of hospitalization.
It has been increasingly used in a variety of clinical settings.
It overcomes flow limitations of low- and intermediate-flow devices by delivering up to 60 litres per minute of heated, humidified gas through nasal prongs.
The primary approach for COVID-19 patients is supportive care which includes oxygen therapy for hypoxemic patients, in which high-flow nasal cannula (HFNC) was reported as effective in improving oxygenation.
This market report also allows you to identify the future opportunity and growth rate of the leading segment based on regions and countries.The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide.
The major players in the High Flow Nasal Cannula market include Great Group Medical Co., Ltd., Salter Labs, TNI Medical Ag, Mek-Ics Co., Ltd., Flexicare Medical Limited.
This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.Get more information on "Global High Flow Nasal Cannula Market Research Report" by requesting FREE Sample Copy athttps://www.valuemarketresearch.com/contact/high-flow-nasal-cannula-market/download-sampleMarket DynamicsRespiratory distress is one of the most common causes of hospitalization.
It has been increasingly used in a variety of clinical settings.
It overcomes flow limitations of low- and intermediate-flow devices by delivering up to 60 litres per minute of heated, humidified gas through nasal prongs.
The primary approach for COVID-19 patients is supportive care which includes oxygen therapy for hypoxemic patients, in which high-flow nasal cannula (HFNC) was reported as effective in improving oxygenation.
